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INTRODUCTION
Food allergy is an important medical and social problem and 
its incidence appears to be on the rise.1 Soy, which belongs to 
the “Big-8 allergenic foods”,2 is widely used by the food industry, 
can be present as excipients in non-food products (gasolines, 
inks, crayons, adhesives, soaps, pharmaceuticals and cosmet-
ics),3 and may act as an aeroallergen causing occupational al-
lergy in rural workers and in individuals involved in soybean 
processing.4-6 Thus, it is difficult for sensitive individuals to 
avoid exposure to these ubiquitous proteins. However, the inci-
dence of soy allergy is lower than generally expected.7-10
The identification and characterization of soy components re-
sponsible for allergy is essential for the development of immu-
no-intervention strategies. Three soybean proteins, Gly m Bd 30 
K/P34, Gly m Bd 28 K/P28 and Gly m 5, have been described as 
major soy allergens based on IgE recognition.11-15 However, the 
in vivo allergenicity has not been investigated. Gly m Bd 30 K/
P34 is an outlying member of the papain-superfamily of cysteine 
proteases.16-18 Despite a mutation in the active site that silences 
the protease activity,16 it has been characterized as a major aller-
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gen,11,12 and several linear B epitopes have been mapped.19,20 
Nonetheless, its clinical relevance should be explored.
Considering the low prevalence of hypersensitivity to soy-
beans, it has been proposed that soy allergy may occur through 
secondary sensitization. Co-sensitization to soy has often been 
described in Central Europe in birch pollen-sensitized pa-
tients.21,22 We have previously shown that Gly m 6 G4 and Gly m 
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5 are recognized by the IgE antibodies of patients allergic to 
milk, although the clinical relevance of this finding requires fur-
ther investigation.23-25 Taking into account the fact that soybean 
proteins are ubiquitous, exposure to soybean in patients is diffi-
cult to discard. A milk-allergic mouse model was used to over-
come this problem, and we previously demonstrated that hy-
persensitivity reactions were elicited in milk-sensitized animals 
exposed to total soybean proteins or Gly m 6 G4. These findings 
showed the potential allergenicity of Gly m 6 G4 as a cross-reac-
tive soy component.23,24,26
In this study, we investigated the recognition of Gly m Bd 30K/
P34 by cow’s milk protein (CMP)-specific antibodies and evalu-
ated the clinical relevance of this cross-reactivity using the milk 
allergy mouse model. We found that P34, one of the main aller-
gens of soy, behaves as a cross-reactive allergen with bovine ca-
seins, which are considered one of the main allergens in cow’s 
milk.27,28 These findings increase our understanding of the clini-
cal intolerance observed in a restricted proportion of milk aller-
gic patients (10%) treated with a soy-based formula.29 In addi-
tion, an allergen immunotherapy could be developed based on 
this biological phenomenon.
 
MATERIALS AND METHODS
Protein extracts and antibodies
Soybean protein (SP) extract was obtained from Glycine max 
L. Merr. seeds as described previously.24 Briefly, seeds were 
crushed and extracted with 0.01 N NaHCO3 at 90°C. The extract 
was centrifuged at 2,500×g for 20 minutes at room temperature 
and lipids were extracted with chloroform overnight at 4°C. The 
extract was dialyzed against distilled water and stored at -20°C 
until use. 
CMP extract was obtained from commercial skimmed milk. 
Proteins were extracted with phosphate-buffered saline pH 7.4 
(10 mg/mL) and filtered. The extract was stored at -20°C until 
use. The presence of soy components in the CMP extract was 
previously discarded by indirect ELISA with SP-specific rabbit 
antiserum.
Sera from 10 pediatric patients diagnosed with milk allergies 
according to history, skin prick test, and serum specific IgE 
were used. Double-blind placebo-controlled food challenge is 
not performed in Argentina for diagnosis; instead, elimination 
of milk from the diet and open challenge is performed. Soy al-
lergy was ruled out based on history and serum IgE against SP. 
Sera from healthy individuals with no allergy history and nor-
mal level of serum IgE, or from patients allergic to aeroallergens 
with no CMP-specific IgE antibodies or history of food allergy, 
were included as negative controls.
Three monoclonal antibodies (mAb) with differential speci-
ficities for α-casein (1D5), β-casein (4C3) and κ-casein (3B5), 
which were characterized previously,30 were used.
Gly m Bd 30K/P34 construct expression and purification
The cDNA coding sequence for P34 (GenBank: DQ324851) 
was obtained by PCR amplification of the cDNA library.31 Am-
plified PCR products were cloned directionally into pENTR/D 
TOPO (Life Technology, S.A. Argentina) and were then trans-
ferred to the pDEST-maltose-binding protein (MBP) destina-
tion vector for expression.32 E. coli BL21 Codon Plus containing 
the constructs pDEST His-MBP-P34 and pDEST His-MBP were 
induced and recombinant proteins were purified as described 
previously.24 Depletion of lipopolysaccharide was performed 
with a Sepharose-polymyxin B resin (Pierce, Rockford, IL, USA). 
Endotoxin determination was performed using the Limulus 
amoebocyte chromogenic assay (LONZA, Buenos Aires, Ar-
gentina). Protein concentration was determined using the 
bicinchoninic acid assay with bovine serum albumin as a stan-
dard (Pierce, Rockford, IL, USA). 
Immunochemical assays
Immunoblotting
Purified P34 and MBP (3 μg) were separated by SDS-PAGE 
and transferred to nitrocellulose membranes. Blocked mem-
branes (3% horse serum) were incubated with patient serum 
(1:5, overnight at 4°C), followed by biotinylated anti-human IgE 
monoclonal antibody (1:3,000, 4 hours at 37°C, Vector Labora-
tories Inc., CA, USA), and finally, with horseradish peroxidase 
(HRP) -streptavidin conjugate (1:3,000, 30 minutes at 37°C, Sig-
ma-Aldrich, MO, USA). Luminol chemiluminescent substrate 
and exposure to X-ray film (Amersham Hyperfilm ECL, GE 
Healthcare Bio-Sciences Corp., USA) were used for band visu-
alization. Membranes were also revealed using the mAbs (1 μg/
mL) followed by mouse immunoglobulin G-specific rat mono-
clonal antibody HRP-conjugate (1:3,000, 1 hour at 37°C Bio-
Rad Laboratories, CA, USA).
Competitive ELISA
Polystyrene microtitre plates were coated with 0.25 µg/well 
α-casein (Sigma-Aldrich, MO, USA) and blocked with 5% horse 
serum. Purified 1D5 mAb was separately incubated with vari-
ous quantities of the soluble inhibitor α-casein, P34 or ovalbu-
min (OVA) as a non-related protein (2 hours at 37°C). This pre-
mixed dilution was then added to the coated wells (30 minutes 
at 37°C). Finally, the secondary antibody was added (1:3,000, 1 
hour at 37°C) and color was developed with o-phenylenedi-
amine. Optical density (OD) was measured at 492 nm.
Flow cytometry-based basophil activation test (BAT)
Basophils were obtained from whole heparinized blood col-
lected from non-allergic human donors using ammonium-
chloride-potassium (ACK) buffer (0.15 M NH4Cl, 10 mM 
KHCO3, 0.1 mM Na2EDTA, pH 7.2) as erythrocyte lysis buffer. 
Total cells were re-suspended in ice-cold lactic acid buffer pH 
3.9 (13.4 mM lactic acid, 140 mM NaCl and 5 mM KCl) for 5 
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minutes for stripping. Cells were washed and re-suspended 
again in 2 mL of saline buffer containing 20% serum from milk 
allergic patients (5 sera), 4 mM Na2EDTA  and 10 mg/mL hepa-
rin (90 minutes at 37°C). Cells were washed with 20 nM HEPES 
buffer pH 7.4 and incubated with HEPES buffer containing 1 
mM CaCl2 (30 minutes at 37°C).33 Cells were then challenged 
with whole milk proteins, SP or the recombinant P34 soy aller-
gen at various concentrations. Saline buffer was used to stop cell 
activation. Finally, washed cells were incubated with 7-amino-
actinomycin (7-AAD) (BD Pharmingen, USA) and biotinylated 
anti-human IgE monoclonal antibody (Vector Laboratories Inc., 
CA, USA), streptavidin-allophycocyanin (APC) (eBioscience, 
USA), phycoerythrin (PE)-conjugated antibody specific to hu-
man CD63 (BD Pharmingen, USA), or monoclonal antibodies 
specific to human CD203c (Macs, Miltenyi Biotec, Germany), 
followed by goat anti-mouse IgG fluorescein isothiocyanate 
(FITC) (Santa Cruz Biotechnology, USA). Fluorescence data 
were acquired with a Becton Dickinson FACSCalibur flow cy-
tometer (Franklin Lakes, NJ, USA) and analyzed with the BD 
CellQuest Pro software and the FlowJo software (Tree Star Inc., 
Ashland, OR, USA). Controls with a non-related protein (OVA) 
or with sera from non-allergic subjects were included.
Sensitization and immune response to antigens
Mice sensitization and challenges
Male 6- to 8-week-old Balb/c mice were purchased from the 
School of Animal Sciences, University of La Plata, and kept un-
der pathogen-free conditions with water and a commercial diet 
provided ad libitum. Mice were grouped into sensitization and 
control groups (n=8 per group). Animals were sensitized es-
sentially as described previously,26 Ten days following the last 
boost, some mice were challenged with 20 mg of CMP or 5 mg 
of SP intragastrically (i.g.), while others were challenged with 5 
μg of P34, 5 μg of β-lactoglobulin (β-Lg) (positive control anti-
gen), or 10 μg of OVA (unrelated control antigen) by sublingual 
(s.l.) administration.
In vitro evaluation of the allergic reaction
Serum specific IgE antibodies were assessed by EAST using 
CNBr-activated cellulose paper discs coupled with CMP (1.75 
mg/mL), SP (0.5 mg/mL), P34 (0.2 mg/mL) or MBP (0.1 mg/
mL), and developed essentially as described previously.26 In ad-
dition, serum specific IgG1 and IgG2a were measured (ELISA) 
using CMP, SP, or P34 at 1 μg/100 μL, or MBP at 0.5 μg/100 μL, 
as described previously.26 Plasma histamine level was mea-
sured using competitive ELISA as described previously.26
To examine T cell activation, cytokines were measured in su-
pernatants of antigen-stimulated spleen cells. Briefly, 24 hours 
following oral challenge, mice were killed, spleens were resect-
ed, and spleen cells were stimulated for 72 hours with CMP (350 
μg/mL), SP (200 μg/mL), P34 (15 μg/mL) or MBP (7.5 μg/mL). 
Production of IL-5, IFN-γ (Invitrogen Corporation, USA) and 
IL-13 (R&D Systems, UK) was assayed by ELISA following the 
manufacturer´s instructions.
In vivo evaluation of the allergic reaction
Symptoms were observed 30-60 minutes following oral chal-
lenge in a blinded fashion by 2 independent investigators, and 
were scored according to Table 1. Cutaneous tests were per-
formed as described previously.26 Briefly, shaved skin was sub-
cutaneously (s.c.) injected with 200 μg of CMP, 400 μg of SP, or 
10 μg of P34 in 50 μL of sterile saline in one flank and with 10 μg 
of MBP or saline in the contra-lateral flank (negative control). 
Evans blue dye was intravenously (i.v.) injected and observa-
tion of a blue color in the first 30 minutes after injection was 
considered a positive cutaneous test.
Ethical considerations
The research was conducted in strict agreement with the inter-
national ethical standards for animal experimentation (Helsinki 
Declaration and its amendments, Amsterdam Protocol of wel-
fare and animal protection and National Institutes of Health, 
USA NIH, guidelines: Guide for the Care and Use of Laboratory 
Animals) and was approved by the local Institutional Animal 
Care and Use Committee at the School of Animal Science (Uni-
versity of La Plata).
Statistical analysis
Statistical analyses were performed using the GraphPad Prism 
5 software. The significance of differences was determined us-
ing an independent-sample t-test or ANOVA test. A P value 
<0.05 was considered to indicate statistical significance.
RESULTS
P34 is in vitro recognized by CMP-specific immunoglobulins 
Human sera containing specific IgE antibodies were used to 
assess the recognition of recombinant P34. Fig. 1A shows that 
P34 was recognized as a coated antigen by 9 of 10 sera from milk 
allergic patients. Additional bands due to partial degradation of 
P34 were detected with some sera. No binding of MBP with sera 
from allergic patients (#3) or of P34 with sera from non-allergic 
Table 1. Clinical scores assigned to triggered symptoms following the oral 
challenge
Score Symptoms
0 No symptoms
1 Scratching and rubbing around the snout and head
2 Puffiness around the eyes and mouth, piloerection, reduced activity   
   and/or decreased activity with increased respiratory rate
3 Respiratory distress, cyanosis around snout and tail
4 No activity upon stimuli, convulsion
5 Death
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subjects and non-milk-allergic patients (#11 and 12) was detect-
ed. To rule out co-sensitization in patients, immunoblotting was 
performed using three casein-specific monoclonal antibodies; 
all mAbs revealed a band corresponding to P34 (Fig. 1B). MBP 
was not recognized.
To rule out the possibility of artifactual reactivity due to new 
epitopes created during antigen coating, P34 was used as a sol-
uble inhibitor in a competitive ELISA using the α-casein-
specific 1D5 mAb (Fig. 1C). The sigmoid-shape of the dose-re-
sponse inhibition curve obtained with P34 as an inhibitor sup-
ported the specificity of the antigen-antibody reaction. Anti-
body binding to the immobilized α-casein (0.25 µg/well) was 
inhibited by 100% with 0.002 mg/mL of soluble α-casein, while 
50% inhibition (IC50) was achieved with 0.0002 mg/mL of 
α-casein and 0.05 mg/mL of P34. No inhibition was observed 
over a wide range of OVA concentrations.
To confirm the cross-reactivity with human IgE antibodies, we 
performed BAT using sera from milk allergic patients. Stripped 
basophils from healthy donors were passively sensitized with 
individual sera containing IgE and then activated with various 
concentrations of milk or soy proteins. A minimum of 100,000 
events per sample were analyzed by flow cytometry and cells 
were gated based on physical properties (Fig. 2AI), 7 AAD-live 
cells (Fig. 2AII), and IgE+ cells (Fig. 2AIII), and were further ana-
lyzed for membrane CD63 and CD203c. Isotype controls were 
used to establish fluorescence thresholds. Percentages of dou-
ble-positive cells were compared between basophils incubated 
with the allergen or PBS, CMP, and SP induced a higher per-
centage of IgE+ CD63+ CD203c+ cells compared with PBS alone 
(18.45%±1.35% and 18.80%±0.5% vs 9.16%±1.26%, respec-
tively) (Fig. 2B). When P34 was used for IgE-dependent baso-
phil activation, we observed 18.5%±0.45% double-positive 
cells. The non-related protein OVA at various concentrations 
resulted in 8.37%±0.31% double-positive cells. In addition, 
there were no statistically significant differences in cell activa-
tion using sera from non-allergic patients (data not shown).
Total soybean proteins trigger acute allergic skin reactions in 
mice orally sensitized with CMP
CMP-sensitized Balb/c mice were used to investigate the clin-
ical relevance of the immunochemical co-recognition (Fig. 3A). 
Intragastically sensitized mice developed hypersensitivity reac-
tions (Fig. 3B) that were scored immediately after oral challenge 
with CMP or SP (Table 1). CMP-sensitized animals showed 
high scores upon challenge with SP, while no symptoms were 
observed in sham mice. To correlate these clinical findings with 
a systemic parameter, histamine was measured (Fig. 3C). We 
observed increased plasma levels in sensitized mice, demon-
strating that the administration of SP or CMP to CMP-sensitized 
animals developed adverse reactions. Next, we examined the 
functionality of IgE antibodies. Subcutaneous injection of CMP 
or SP resulted in a local and distant inflammation within min-
utes (Fig. 3D). Injection of saline induced negative results in 
sham and sensitized animals.
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P34 is recognized by serum antibodies and spleen cells from 
milk allergic mice
We next explored whether soy proteins were recognized by 
the secreted T-helper 2 (Th2)-associated antibodies. We found 
that SP and P34 were recognized by mouse CMP-specific IgE 
and IgG1 antibodies. No IgG2a specific antibodies were detect-
ed in sensitized or sham animals (Fig. 4A). To correlate the hu-
moral immune response with the cellular immunity, the anti-
gen-specific T-cell response and cytokine production were ex-
amined. A significant increase in the secretion of Th2 cytokines 
(IL-5 and IL-13) was detected in sensitized mice challenged 
with CMP or SP, while secretion of IFN-γ remained unchanged 
(Fig. 4B). Upon stimulation of spleen cells with detoxified P34 
protein, IL-5 and IL-13 were secreted; in contrast, MBP did not 
induce cell stimulation. 
P34 induces a positive cutaneous reaction and elicits 
immediate hypersensitivity symptoms
Consistent with the in vitro findings, we observed a positive 
cutaneous test with P34 (Fig. 4C), demonstrating that this mol-
Ι ΙΙ ΙΙΙ
Fig. 2. Basophil activation test by flow cytometry. Basophils from healthy donor subjects were stripped and passively sensitized with milk-specific IgE-containing 
sera from milk-allergic patients (n=5). (A) Cells were selected according to physical parameters (AI), live cells (AII) and IgE-membrane-bound cells (AIII). (B) Double-
positive cells expressing CD63 and CD203c were analyzed in the later gate when different allergens at various concentrations were used to induce basophil activa-
tion. Results corresponding to a representative experiment are shown. (C) Percentages of CD63+ CD203c+ cells with all positive sera analyzed. Data represent 
means±SEM % of double-positive basophils. Statistically significant difference by ANOVA: *P<0.05 , **P<0.01, ***P<0.005, vs PBS group. CMP, cow’s milk pro-
teins; SP, soy proteins; OVA, ovalbumin.
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Fig. 3. Experimental design, clinical symptoms and histamine levels. (A) Schematic drawing of the experimental protocol: BALB/c mice (n=8 per group) were sub-
jected to weekly intragastric sensitization with cholera toxin and CMP from day 0 through 35. Challenge was performed at day 45 by intragastric (CMP or SP) (n=7 
per group) or sublingual (β-Lg, P34 or OVA) (n=5 per group) protein administration. Control mice received only CMP and were then orally challenged. (B) Symptoms 
were observed 30 minutes following challenge with CMP or SP and scored according to Table 1 . (C) Quantification by ELISA of histamine following oral challenge 
(mean values±SEM). (D) Cutaneous test: sensitized and control mice were subcutaneously injected with CMP, SP and saline (n=4 per group). The presence of blue 
color in the skin within minutes after injection was considered a positive cutaneous test. Statistically significant difference by ANOVA: ***P<0.005. CMP, cow’s milk 
proteins; SP, soy proteins; CT, cholera toxin.
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ecule has at least two B epitopes capable of cross-linking mem-
brane-bound IgE. Furthermore, the negative results obtained 
with all proteins in sham mice demonstrated that oral chal-
lenge with recombinant protein did not sensitize the mice.
Since sensitization does not always correlate with the clinical 
situation, a sublingual challenge was performed with P34 and 
control proteins in sham and sensitized animals. P34 and β-Lg 
strongly induced immediate symptoms in CMP-sensitized 
mice (Fig. 4D). In contrast, no clinical signs were induced by 
non-related OVA.
DISCUSSION
Although the population is highly exposed to soy allergens, 
exclusive soy allergy is rare.7 Instead, soy allergy is mainly en-
countered in patients primarily sensitized to other allergens 
due to cross-recognition of common epitopes.7 Despite the 
wide use of soybean formulae for infant feeding,34 there are few 
indications in atopic children. Allergy to soy proteins has been 
described in a small proportion of patients,35 and a randomized 
trial demonstrated that soy formula feeding does not induce an 
allergic reaction in milk-allergic children. Furthermore, some 
groups documented a clinical intolerance to soy-based formula 
in a small proportion of IgE-mediated milk allergic patients 
(<15%) that received soy products as a diary substitute.36 The 
American Academy of Pediatrics (AAP) and ESPGHAN recom-
mended the use of extensively hydrolyzed CMP or a free amino 
acid-based formula as a first-line therapy if extensive hydro-
lyzed formula is not tolerated during CMA treatment. However, 
soy and rice protein-based infant formula are appropriate alter-
natives for these patients. ESPGHAN, AAP and DRACMA con-
sensus recommended that soy formula should not be used in 
Fig. 4. Immune responses to milk and soy proteins. (A) Specific IgE (by EAST), IgG1 and IgG2a (by ELISA) in serum of milk-sensitized mice (mean values±SEM). (B) 
Levels of IL-5, IL-13 and IFN-γ (by ELISA) in supernatants of stimulated spleen cells (mean values±SEM). Results correspond to a single experiment with at least 
three mice per condition representative of three separate experiments with similar results. (C) Cutaneous test in sensitized mice subcutaneously injected with P34 in 
the right flank and MBP in the left flank. (D) Clinical scores assigned to symptoms observed within 30 minutes following the sublingual challenge with β-Lg, P34 or 
OVA. (A) and (B) were analyzed by Student’s t-test and (D) with ANOVA test. Statistically significant differences are shown as: *P<0.05, **P<0.01, ***P<0.005, 
CMP, cow’s milk proteins; SP, soy proteins; MBP, maltose-binding protein, β-Lg, beta lactoglobulin; OVA, ovalbumin.
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children (healthy or with food allergy) during the first 6 months 
of life as an initial treatment because of nutritional risks. In Ar-
gentina, soybean based-formula are commonly used as a dairy 
substitute for economic and acceptability reasons in children 
older than 6 months, and allergists are facing the problem that 
some CMA patients do not tolerate soy-based formula.37 The 
majority of these patients have serum IgE that recognizes SP; 
however, co-sensitization cannot be ruled out.37
We propose that the intolerance observed in a small number 
of children may be due to cross-reactivity between soy proteins 
and bovine caseins. We identified common structural determi-
nants between caseins and two soybean proteins, Gly m 5 al-
pha subunit and Gly m 6 G4,23-25 and explored this immuno-
chemical cross-reactivity using the IgE-mediated mouse model 
of CMA.26 In this study, we provide in vivo and in vitro experi-
mental data that confirm the cross reactivity among non-phy-
logenetically related proteins, focusing on the major soybean 
allergen: Gly m Bd 30 k or P34.
Although the in vitro allergenicity of P34, including B and T 
epitopes,38 has been thoroughly described, its clinical relevance 
requires further study. In this report, we show that P34 was rec-
ognized by serum IgE of allergic patients, different casein-spe-
cific monoclonal antibodies, and CMP-specific IgE and IgG1 
antibodies from milk-allergic mice. Consistent with the Th2-bi-
ased immune response, an immediate cutaneous reaction and 
hypersensitivity symptoms were observed in sensitized mice 
following oral exposure to P34. These findings are suggestive of 
at least two IgE epitopes with a surface distribution that en-
abled functional synapses between the allergenic molecule and 
the sensitized cells in different mucosa.
Unlike other cysteine proteases from tree and grass pollens, 
which have been associated with disruption of the protease–
antiprotease balance at mucosal tissues,39 the allergenicity of 
P34 could be due to other physicochemical characteristics and 
not to protease activity. Here, we have shown using a variety of 
approaches that P34 contains B and T cross-reactive epitopes 
with CMP. This recombinant allergen promoted hypersensitive 
symptoms following sublingual challenge and induced a posi-
tive skin test in milk-sensitized mice. These findings demon-
strate that the immunochemical cross-reactivity described for 
P34 may be clinically relevant. Further studies are required to 
characterize the differential immune response observed with 
the cross-reactive soy allergens and to delineate the scope and 
limitation of serum cross-reactive IgE. In this sense, animal 
models facilitate the investigation of the biological significance 
of this immunochemical cross-reactivity.
In conclusion, we identified P34 as a new cross-reactive soy 
protein that triggers hypersensitivity reactions in an IgE-medi-
ated milk-allergic mouse model. This cross-recognition may ex-
plain the cross-allergenicity observed in some milk-allergic pa-
tients.
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